While prognostic differences between HER2-low status and HER2 IHC 0 breast cancers have been reported, most studies found small or no differences in prognosis after adjusting for HR status [35,36,37], including in CDK4/6i-treated patients [38,39]. This evidence concerns the gene ERBB2 and breast cancer.